Marcus Theatres' stock rises as Beyoncé concert film set for release
By James Rogers
Major concert films are in the spotlight, boosted by high-profile tours from Beyoncé and Taylor Swift
Marcus Corp.'s stock (MCS) rose 0.9% Monday after Marcus Theatres announced that it will show the concert film of Beyoncé's "Renaissance World Tour."
Starting Dec. 1, "Renaissance: A Film by Beyoncé," will show on Thursdays, Fridays, Saturdays, and Sundays, the company said, with special early screenings on Nov. 30, at Marcus Theatres and Movie Tavern screens across 17 states. Marcus Corp.'s stock is up 8.7% in 2023.
Related: Makers of Beyoncé concert film reportedly in talks with AMC for theatrical run
On Saturday Variety reported that AMC Entertainment Holdings Inc. (AMC) is in advanced talks to distribute Beyoncé's concert film directly through its theaters.
Major concert films are in the spotlight, boosted by high-profile tours from Beyoncé and Taylor Swift, whose "Taylor Swift The Eras Tour" film hits theaters Oct. 13. AMC recently announced that the film had shattered the company's record for single-day advance ticket sales, with $26 million in ticket revenue sold on Aug. 31. AMC rival Cinemark Holdings Inc. (CNK) is offering Private Swiftie Parties, where fans can hire a private auditorium to watch "Taylor Swift The Eras Tour."
Related: Cinemark launces Private Swiftie Parties to watch Taylor Swift's New Eras concert film
AMC's stock rose 4.3% Monday, compared with the S&P 500 Index's SPX decline of 0.1%. Cinemark's stock rose 1.3% Monday.
-James Rogers
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-02-23 1011ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks